MA33662B1 - Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète - Google Patents

Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète

Info

Publication number
MA33662B1
MA33662B1 MA34760A MA34760A MA33662B1 MA 33662 B1 MA33662 B1 MA 33662B1 MA 34760 A MA34760 A MA 34760A MA 34760 A MA34760 A MA 34760A MA 33662 B1 MA33662 B1 MA 33662B1
Authority
MA
Morocco
Prior art keywords
diabetes
treatment
pharmaceutical use
spiropiperidine compounds
spiropiperidine
Prior art date
Application number
MA34760A
Other languages
Arabic (ar)
English (en)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33662(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33662B1 publication Critical patent/MA33662B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur un composé de la formule :(i) ou sur un sel de qualité pharmaceutique de celui-ci, ainsi que sur une composition pharmaceutique et sur un procédé pour traiter le diabète.
MA34760A 2009-10-15 2012-04-09 Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète MA33662B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11
PCT/US2010/052126 WO2011046851A1 (fr) 2009-10-15 2010-10-11 Composés de spiropipéridine et son utilisation pharmaceutique pour le traitement du diabète

Publications (1)

Publication Number Publication Date
MA33662B1 true MA33662B1 (fr) 2012-10-01

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34760A MA33662B1 (fr) 2009-10-15 2012-04-09 Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète

Country Status (24)

Country Link
US (1) US8383642B2 (fr)
EP (1) EP2488500A1 (fr)
JP (1) JP2013508279A (fr)
KR (1) KR20120051777A (fr)
CN (1) CN102574807A (fr)
AR (1) AR078522A1 (fr)
AU (1) AU2010307094A1 (fr)
BR (1) BR112012008889A2 (fr)
CA (1) CA2777775A1 (fr)
CL (1) CL2012000921A1 (fr)
CO (1) CO6531458A2 (fr)
CR (1) CR20120177A (fr)
DO (1) DOP2012000105A (fr)
EA (1) EA201270560A1 (fr)
EC (1) ECSP12011799A (fr)
IL (1) IL218344A0 (fr)
MA (1) MA33662B1 (fr)
MX (1) MX2012004420A (fr)
NZ (1) NZ598972A (fr)
PE (1) PE20121437A1 (fr)
TN (1) TN2012000152A1 (fr)
TW (1) TW201124415A (fr)
WO (1) WO2011046851A1 (fr)
ZA (1) ZA201202560B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174398A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
AP3280A (en) 2009-03-23 2015-05-31 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as TRPA1 modulators
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PE20121639A1 (es) 2009-12-25 2012-12-02 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
PL2683251T3 (pl) 2011-03-11 2021-12-13 Intercontinental Great Brands Llc Sposób wytwarzania wielowarstwowych wyrobów cukierniczych
AU2012248629A1 (en) 2011-04-27 2013-11-28 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
TWI537262B (zh) 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
WO2013139341A1 (fr) * 2012-03-20 2013-09-26 Syddansk Universitet Modulateurs de récepteurs gpr120
WO2013185766A1 (fr) * 2012-06-15 2013-12-19 Syddansk Universitet Modulateurs du récepteur gpr120
AU2013344604B2 (en) 2012-11-16 2017-07-27 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
IN2013MU03577A (fr) 2013-11-14 2015-07-31 Cadila Healthcare Ltd
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
AU2015331074B2 (en) * 2014-10-17 2018-11-15 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
PT3737470T (pt) 2018-01-08 2023-03-02 Celon Pharma Sa Derivados do ácido 3-fenil-4-hexinoico como agonistas de gpr40
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
IL291985A (en) 2019-10-07 2022-06-01 Kallyope Inc gpr119 agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
EP4172162A1 (fr) 2020-06-26 2023-05-03 Kallyope, Inc. Activateurs d'ampk

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1385514T5 (da) * 2001-04-18 2009-03-09 Euro Celtique Sa Spiroinden- og spiroindanforbindelser
WO2004089307A2 (fr) * 2003-04-04 2004-10-21 Merck & Co. Inc. Derives de spiropiperidine acyles utilises comme agonistes vis-a-vis du recepteur de melanocortine-4
US7504506B2 (en) * 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CN1946666A (zh) 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
WO2007033002A1 (fr) * 2005-09-14 2007-03-22 Amgen Inc. Acides propanoïques 3-substitués par un groupement 4-hydroxyphényle à conformation contrainte pouvant être employés dans le traitement de troubles métaboliques
CA2662242C (fr) 2006-09-07 2012-06-12 Amgen Inc. Composes benzo-fusionnes destines a etre utilises dans le traitement de troubles metaboliques
WO2009054479A1 (fr) * 2007-10-26 2009-04-30 Japan Tobacco Inc. Compose spiro-cyclique et utilisation de ce compose a des fins medicales
ES2469824T3 (es) * 2007-11-21 2014-06-20 Janssen Pharmaceutica N.V. Espiropiperidinas para su uso como inhibidores de la triptasa
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
DOP2012000105A (es) 2013-01-31
MX2012004420A (es) 2012-05-08
NZ598972A (en) 2013-06-28
CN102574807A (zh) 2012-07-11
US8383642B2 (en) 2013-02-26
AU2010307094A1 (en) 2012-04-19
JP2013508279A (ja) 2013-03-07
US20110092531A1 (en) 2011-04-21
ECSP12011799A (es) 2012-07-31
EA201270560A1 (ru) 2012-09-28
CO6531458A2 (es) 2012-09-28
CA2777775A1 (fr) 2011-04-21
EP2488500A1 (fr) 2012-08-22
AR078522A1 (es) 2011-11-16
KR20120051777A (ko) 2012-05-22
TN2012000152A1 (en) 2013-12-12
TW201124415A (en) 2011-07-16
ZA201202560B (en) 2013-09-25
PE20121437A1 (es) 2012-10-26
CL2012000921A1 (es) 2012-09-14
CR20120177A (es) 2012-06-06
IL218344A0 (en) 2012-04-30
WO2011046851A1 (fr) 2011-04-21
BR112012008889A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
MA33662B1 (fr) Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète
MA33840B1 (fr) Nouveau composé de spiropipéridine
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA27946A1 (fr) Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d'etats pathologiques.
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA32171B1 (fr) Compose heterocyclique
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA30652B1 (fr) Composes organiques
MA32965B1 (fr) Derives de sulfonamides
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
MA33428B1 (fr) Agonistes du gpr119
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA40895A (fr) Synthèse de copanlisib et son sel de dichlorhydrate
MA32904B1 (fr) Composes de purine
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires